Astrocytoma

The results demonstrated that GBM-derived EVs significantly contribute to astrocyte phenotypic alterations associated with invasion and metastasis. These findings highlight the importance of EV-mediated intercellular communication in GBM progression and suggest further in vivo studies to elucidate their role in central nervous system invasion.

P2, N=55, Recruiting, Stephen Bagley, MD, MSCE | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027

P3, N=468, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting --> Recruiting

P2, N=36, Suspended, Mayo Clinic | Not yet recruiting --> Suspended

These results highlight the potential of ¹⁸F-DOPA-PET and advanced MRI sequences as valuable complements to standard RANO 2.0 MRI evaluations for assessing treatment response in glioma patients undergoing IDHi therapy.

Astrocytoma was the most prevalent pathology in this study. H3K27M mutation did not significantly affect survival in high-grade spinal astrocytoma, while high Ki-67 and p53 expression correlated with poorer prognosis. Tumor length was associated with short-term but not long-term neurological function. Long-term neurological outcomes were mainly linked to inherent tumor properties and postoperative neurological status; postoperative PLR changes may partly indicate long-term neurological function.

P2, N=40, Recruiting, University of Vermont Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Dec 2026

These findings define a previously unrecognized MELK-NS-p53 signaling axis that links kinase activity to the regulation of the cell cycle. Our fundings provide mechanistic insights into glioblastoma pathogenesis and suggest that targeting the MELK-NS pathway may be a potential therapeutic strategy for high-grade gliomas.

Drospirenone may exhibit potential as a prophylactic agent in vitro during the early phases of neuroinflammation, though its efficacy appears limited in models of chronic or prolonged inflammation. These preliminary findings require in vivo validation, and future studies could explore possible synergistic effects with other treatments or alternative dosing strategies for neuropathic pain management.

This review focuses on contemporary pharmacotherapeutic approaches used in the management of glioblastoma, IDH-wildtype, including temozolomide-based chemotherapy, corticosteroids for edema control, and antiangiogenic therapy in recurrent disease, with particular emphasis on their clinical efficacy and limitations...Particular attention is given to ivosidenib, a selective inhibitor of mutant IDH1, currently evaluated for the treatment of astrocytoma, IDH-mutant, grade 4...Finally, innovative drug-delivery technologies designed to overcome the blood-brain barrier are briefly discussed as complementary strategies that may enhance the efficacy of both conventional and targeted therapies. Overall, future advances in the treatment of diffuse gliomas will likely depend on the integration of molecularly targeted agents, predictive biomarkers, and advanced delivery platforms aimed at improving patient survival and quality of life.

However, we also note that this field remains largely in the preclinical research stage and has not yet revolutionized clinical practice. This review is intended for biological scientists and clinicians who find traditional bioinformatic tools difficult to use.

P3, N=365, Recruiting, Nuvation Bio Inc. | Phase classification: P2 --> P3 | N=125 --> 365 | Trial completion date: Mar 2028 --> Dec 2030 | Trial primary completion date: Dec 2027 --> Dec 2028